Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding
Completed
- Conditions
- Upper Gastrointestinal Bleeding
- Registration Number
- NCT01155401
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
- Written informed consent provided prior the start of participation in the study.
Exclusion Criteria
- Subjects who are unwilling or unable to provide informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number and percentage of patients with drug-induced upper gastrointestinal bleeding About 1 year
- Secondary Outcome Measures
Name Time Method Number and percentage of patients with each symptom and each Forrest class of upper gastrointestinal bleeding About 1 year Number and percentage of patients with each type of bleeding outcomes who received different types of hemostatic therapy About 1 year Number and percentage of patients with concomitant diseases contributing to drug-induced upper gastrointestinal bleeding and those who receive NSAIDs, antiplatelet agents, anticoagulants, steroids or combination therapy About 1 year
Trial Locations
- Locations (1)
Research Site
🇷🇺Moscow, Russian Federation